Prestige Consumer Healthcare (NYSE:PBH) Lowered to “Neutral” Rating by Sidoti

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by Sidoti from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday,Briefing.com Automated Import reports. They currently have a $90.00 target price on the stock. Sidoti’s price objective indicates a potential upside of 6.82% from the company’s current price.

PBH has been the subject of several other research reports. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock opened at $84.25 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The company has a market capitalization of $4.16 billion, a P/E ratio of 20.50, a P/E/G ratio of 2.37 and a beta of 0.49. The company’s 50-day simple moving average is $76.78 and its two-hundred day simple moving average is $71.91. Prestige Consumer Healthcare has a one year low of $57.95 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same period last year, the firm earned $1.07 earnings per share. The company’s quarterly revenue was down .9% on a year-over-year basis. As a group, equities analysts anticipate that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,810 shares of company stock worth $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after acquiring an additional 894 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare by 11.0% in the third quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after purchasing an additional 1,715 shares during the period. Coldstream Capital Management Inc. purchased a new position in shares of Prestige Consumer Healthcare in the third quarter valued at $205,000. Geode Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after acquiring an additional 50,961 shares during the last quarter. Finally, M&T Bank Corp boosted its stake in Prestige Consumer Healthcare by 23.8% during the 3rd quarter. M&T Bank Corp now owns 4,594 shares of the company’s stock valued at $331,000 after acquiring an additional 882 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.